Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Anthos Therapeutics
Biotech
Novartis narrows anticoagulant's focus after losing to Eliquis
A little over a year after reabsorbing its anticoagulant abelacimab, Novartis has now terminated two phase 3 trials for the antibody.
Darren Incorvaia
Apr 22, 2026 4:00am
Novartis inks $925M Anthos takeover to rejoin clot-busting race
Feb 11, 2025 5:21am
Trevena teeters on edge with C-suite shakedown—Chutes & Ladders
Nov 8, 2024 8:30am
Xaira, Anthos, CureVac & more—Chutes & Ladders
Apr 26, 2024 8:30am
Blackstone's $250M bet beats Xarelto in phase 2 bleeding trial
Sep 18, 2023 6:00am
Alchemab CEO resigns citing 'personal reasons'—Chutes & Ladders
May 27, 2022 9:30am
